Microimaging ultrasound developer VisualSonics is introducing new molecular imaging capabilities for its Vevo 770 microultrasound system at this week's American Association for Cancer Research (AACR) meeting in Washington, DC.
An initial molecular application involves the measurement of relative expression of angiogenesis using VEGFR-2 as a biomarker, according to the company. Researchers are using the microultrasound system to longitudinally study and quantify tumor growth and blood flow on the same subject over time, as well as visualize the vascular function of an entire tumor.
The company's Vevo 770 system is the subject of several oral and poster presentations at the meeting, according to the Toronto-based company.
By AuntMinnie.com staff writers
April 3, 2006
Related Reading
VisualSonics adds new cardiac capabilities, March 9, 2006
VisualSonics taps Lindner, February 23, 2006
VisualSonics books 200th Vevo sale, February 7, 2006
VisualSonics licenses contrast agent, January 26, 2006
Copyright © 2006 AuntMinnie.com
